Next Phase Newsletter

A venture capital firm founded in 2016 and is headquartered in the USA is currently on their second fund, and the typical check size is flexible, with a typical first check for coming at the seed through series A stage between $1M-5M. The firm is open to both leading or following the investments, but prefers to lead at the seed stage.  The firm focuses on companies located in the US.

The firm is looking for new investment opportunities in sectors focused on applied biology and chemistry, including the therapeutics and diagnostics sectors as well as sustainability, synthetic biology, agtech, and other industrial sectors. The firm is opportunistic in terms of sub-sectors and indications, including all phases of development for therapeutics and various use-cases of synthetic biology. The firm is not typically interested in healthcare services or healthcare IT.

The firm invests in companies in the US and likes to see second or third time entrepreneurs, however the firm will back bold first time entrepreneurs with compelling technologies. The firm is open to both leading or following the investment, and could seek a board seat in certain deals.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science research tools manufacturer based in Western Europe with offices worldwide is interested in partnering with companies developing cutting-edge products that are a strategic fit for the firm’s portfolio. The firm is looking for novel product line addition opportunities globally and possible investments in early stage companies located in North America or Europe who are pursuing technology-leading approaches in the firm’s selected application fields.

The firm is focused on investing in companies that are developing products used in research labs, including consumables, bioprocess and lab automation equipment, and digital tools used by research scientists. The firm generally invests in companies with products that are at the commercial stage. The firm is targeting emerging, non-public companies who are pursuing applications in the areas of Molecular Biology, AI/Digital and Cell Biology.

The firm is flexible about partnering structure and open to a range of approaches including licensing, co-development, equity investments and acquisitions. The firm is a first-for-the-company, corporate venture fund with a charter towards select, new business line-directed equity investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm and incubator that was established in 2020 and is headquartered in USA has about USD 50 million in assets under management. The firm prefers to participate in early-stage and seed (pre-Series A) financing as well as later-stage and pre-IPO (post-Series B and C) financing while avoiding the middle-stages. The firm manages an evergreen fund with between USD 10 million and USD 20 million of available capital per year. The firm typically makes around 3 or 4 investments per year with typical initial allocation size between USD 2 million and USD 10 million for early-stage companies and around USD 10 million for later-stage companies. The firm utilizes various capital structures as determined on a case- by-case basis and has experience with equity investments and convertible loans. The firm primarily invests in companies based in the United States and China but is open to considering all global opportunities as well.

The firm is primarily interested in investing in companies in the biotechnology therapeutics and medical technology sectors. The firm will consider all modalities across these sectors but has expertise in molecule development and prefers to avoid medical devices. The firm has no experience in digital health but will consider investments in the diagnostics sector but prefers to focus on genomics and biomarker diagnostics. The firm will invest in therapeutics that are pre-clinical or in Phase I to Phase III of clinical trials as well as medical technology and diagnostics that are in development or clinical. The firm is disease agnostic and will consider companies across all indications but has experience investing in cancer and autoimmune related technologies.

The firm prefers to work with experienced management teams are dedicated to their technology and their company. The firm is an active investor and will take a board seat on a case-by-case basis depending on investment size. Plaisance Capital Management will act as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Canada was founded by a leading venture capital firm’s former healthcare investment team, who has a successful track record of identifying, building, and growing life science companies. The firm’s newest fund will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2020 and based in the US is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with check sizes between 5 – 10 million USD. The firm prefers to lead the financing rounds but is open to co-investing. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based investment firm was founded with a focus on early stage healthcare companies. The firm currently has 34 companies in their portfolio with 4 exits. The firm invests in all 4 life science sectors and the typical check size ranges from $100K – 500K and typically helps fill out existing rounds once there is a lead investor in-place. The firm generally seeks to make investments into emerging life science companies in Pre-Seed, Seed and Series A stages. The firm is US focused in terms of geographic preference, but will occasionally look outside of the US.

The firm invests across all life science verticals and is open to all 4 sectors. The firm looks for novel technologies in biotech, medtech, digital health therapeutics, and diagnostics. In terms of biotech companies, the firm focuses on biotechnology platforms rather than single asset biotech companies. The firm is agnostic to both subsector and indication and is open to both pre-clinical therapeutic companies as well as all three stages of medical devices.

The firm is open to all types of management teams, with a goal to democratize who gets funding in the life science space. The firm is looking for diversity in the management team to combine ideas and skill set. The firm prefers to co-invest rather than lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm that was established in 2015 and is headquartered in Western Europe. The firm will consider pre-seed investments but is primarily looking to participate in the Seed to Series A financings of early-stage companies with typical pre-money valuation usually between USD 5 million and USD 30 million. Average ticket size is USD 0.5 million. The firm currently participates in equity investments as well as convertible debt. The firm historically has made around ten new investments per year. The firm is focused on partnering with companies based in Western Europe but will consider global opportunities.

The firm is primarily interested in investing in companies in the medical technology and digital health sectors but will also consider those in the wearables and diagnostics sector as well. The firm is open to all modalities within the medical technology and digital health sectors but prefers diagnostic companies to be focused on devices rather than genomics or in vitro diagnostics. The firm will not consider investments in biotech or pharma companies. The firm prefers to invest in pre-market technologies with some proof of pre-clinical data available and will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm will consider companies across all disease indications but prefers to avoid complex disease indications such as the oncology space.

The firm is open to working with both inexperienced and experienced management teams. The firm looks to work with management teams that are efficient and work well together. The firm will sometimes take a board seat as determined on a case-by-case basis. The firm normally prefers to co-invest but will occasionally take a lead role in investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.